In NASH one thing to consider is that the main thi

In NASH one thing to consider is that the main thing the FDA is looking for is reduction in fibrosis, At 750mg with the large difference in cT1 outcomes vs. placebo doubling the number of patients would easily make it statistically significant.

Quote:

---

Mean change cT1 was significantly reduced in the 350 mg group vs placebo (-24.38 ms vs +27.64 ms, p = 0.021) but not in the 700 mg group (-2.73 ms vs +27.64 ms, p = 0.059).

---